Abstract
Prion diseases are rare fatal neurodegenerative disorders that may either occur sporadically, or be inherited or infectiously acquired in humans. Irrespective of etiology, they can be transmitted to other individuals, this fact being responsible for the public attention prion diseases have received especially since the nineteen nineties, when a new variant of Creutzfeldt-Jakob disease linked to the consumption of prion contaminated beef occurred for the first time in Great Britain. The infectious particle, termed prion, is presumably composed exclusively of a misfolded, partially proteaseresistant conformer (PrPSc) of a normal cell surface protein, the cellular prion protein (PrPC). The pathogenesis of prion diseases comprises entry, spread, and amplification of infectivity in the body periphery in infectiously acquired forms, as well as mechanisms of neuronal cell death in the central nervous system in all disease subtypes. Most experimental therapeutic approaches are either targeted to PrPC or PrPSc, or to the process of conversion from PrPC to PrPSc. Neuroprotective strategies aiming at an interruption of central nervous system pathogenesis have also been tested, albeit with only moderate success. In this review, we discuss actual and potential drug targets in the context of the pathogenic mechanisms of prion diseases.
Keywords: Prions, Creutzfeldt-Jakob disease, scrapie, drug targets, therapy, pathogenesis, stress, neurodegeneration
CNS & Neurological Disorders - Drug Targets
Title: The Pathogenic Mechanisms of Prion Diseases
Volume: 6 Issue: 6
Author(s): T. Voigtlander and U. Unterberger
Affiliation:
Keywords: Prions, Creutzfeldt-Jakob disease, scrapie, drug targets, therapy, pathogenesis, stress, neurodegeneration
Abstract: Prion diseases are rare fatal neurodegenerative disorders that may either occur sporadically, or be inherited or infectiously acquired in humans. Irrespective of etiology, they can be transmitted to other individuals, this fact being responsible for the public attention prion diseases have received especially since the nineteen nineties, when a new variant of Creutzfeldt-Jakob disease linked to the consumption of prion contaminated beef occurred for the first time in Great Britain. The infectious particle, termed prion, is presumably composed exclusively of a misfolded, partially proteaseresistant conformer (PrPSc) of a normal cell surface protein, the cellular prion protein (PrPC). The pathogenesis of prion diseases comprises entry, spread, and amplification of infectivity in the body periphery in infectiously acquired forms, as well as mechanisms of neuronal cell death in the central nervous system in all disease subtypes. Most experimental therapeutic approaches are either targeted to PrPC or PrPSc, or to the process of conversion from PrPC to PrPSc. Neuroprotective strategies aiming at an interruption of central nervous system pathogenesis have also been tested, albeit with only moderate success. In this review, we discuss actual and potential drug targets in the context of the pathogenic mechanisms of prion diseases.
Export Options
About this article
Cite this article as:
Voigtlander T. and Unterberger U., The Pathogenic Mechanisms of Prion Diseases, CNS & Neurological Disorders - Drug Targets 2007; 6 (6) . https://dx.doi.org/10.2174/187152707783399175
DOI https://dx.doi.org/10.2174/187152707783399175 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cannabinoids: Novel Medicines for the Treatment of Huntingtons Disease
Recent Patents on CNS Drug Discovery (Discontinued) Biomarkers and Cellular Signal Detection for Alzheimer’s Disease, Stroke, and Immune System Mediated Disorders
Current Neurovascular Research Editorial [Hot Topic: Cognition Therapeutics (Guest Editor: Miao-Kun Sun)]
Current Drug Targets - CNS & Neurological Disorders Why Fish and Fruit are Better than Fish and Chips in the Aging Process
Current Nutrition & Food Science Alzheimer’s Disease: New Concepts on the Role of Autoimmunity and NLRP3 Inflammasome in the Pathogenesis of the Disease
Current Neuropharmacology Targeting the Progression of Parkinsons Disease
Current Neuropharmacology Ginkgo Biloba Extract (EGb 761) and CNS Functions Basic Studies and Clinical Applications
Current Drug Targets Neuron-Microglia Interactions in Motor Neuron Degeneration. The Inflammatory Hypothesis in Amyotrophic Lateral Sclerosis Revisited
Current Medicinal Chemistry Brain-on-a-chip Devices for Drug Screening and Disease Modeling Applications
Current Pharmaceutical Design GEMSP: A New Therapeutic Approach to Multiple Sclerosis
Central Nervous System Agents in Medicinal Chemistry Alzheimers Disease and Retinal Neurodegeneration
Current Alzheimer Research Advanced Tools of Regenerative Medicine for Neurodegenerative Diseases
Recent Patents on Regenerative Medicine Amyloid-Beta Protein Clearance and Degradation (ABCD) Pathways and their Role in Alzheimer's Disease
Current Alzheimer Research Editorial [Continue the Great Journey of Success!]
Current Molecular Medicine Novel Therapeutic Targets for the Treatment of Depression
Current Medicinal Chemistry - Central Nervous System Agents Inhalational Anesthetic Sevoflurane Rescues Retina Function in Alzheimer’s Disease Transgenic Drosophila
Current Alzheimer Research Role of the APP Non-Amyloidogenic Signaling Pathway and Targeting α-Secretase as an Alternative Drug Target for Treatment of Alzheimers Disease
Current Medicinal Chemistry At the “Junction” of Spinal Muscular Atrophy Pathogenesis: The Role of Neuromuscular Junction Dysfunction in SMA Disease Progression
Current Molecular Medicine TRPC Channels and their Implications for Neurological Diseases
CNS & Neurological Disorders - Drug Targets D-amino Acids as Novel Blood-based Biomarkers
Current Medicinal Chemistry